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Abstract
Seckel syndrome is a recessively inherited dwarfism disorder characterized by microcephaly and a unique head profile.
Genetically, it constitutes a heterogeneous condition, with several loci mapped (SCKL1-5) but only three disease genes
identified: the ATR, CENPJ, and CEP152 genes that control cellular responses to DNA damage. We previously mapped a
Seckel syndrome locus to chromosome 18p11.31-q11.2 (SCKL2). Here, we report two mutations in the CtIP (RBBP8) gene
within this locus that result in expression of C-terminally truncated forms of CtIP. We propose that these mutations are the
molecular cause of the disease observed in the previously described SCKL2 family and in an additional unrelated family
diagnosed with a similar form of congenital microcephaly termed Jawad syndrome. While an exonic frameshift mutation
was found in the Jawad family, the SCKL2 family carries a splicing mutation that yields a dominant-negative form of CtIP.
Further characterization of cell lines derived from the SCKL2 family revealed defective DNA damage induced formation of
single-stranded DNA, a critical co-factor for ATR activation. Accordingly, SCKL2 cells present a lowered apoptopic threshold
and hypersensitivity to DNA damage. Notably, over-expression of a comparable truncated CtIP variant in non-Seckel cells
recapitulates SCKL2 cellular phenotypes in a dose-dependent manner. This work thus identifies CtIP as a disease gene for
Seckel and Jawad syndromes and defines a new type of genetic disease mechanism in which a dominant negative mutation
yields a recessively inherited disorder.
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Introduction
Seckel syndrome (SS) belongs to the group of genome instability
disorders collectively referred to as DNA-damage response (DDR)
and repair defective syndromes [1]. While cancer predisposition is
often associated with such syndromes, only a few cancers have
been reported for SS patients. Instead, SS pathogenesis is
primarily based on marked growth and neurological impairments.
Moreover, in contrast to some other repair defective syndromes,
SS is a heterogeneous disease with five independent loci identified:
SCKL1, which bears a mutation that creates an alternative
splicing site in the ATR gene [2]; SCKL2, previously mapped by
us in the chromosomal region 18p11.31-q11.2 [3]; SCKL3,
mapped in the region 14q23-q24 [4]; SCKL4 that has a mutation
in the CENPJ gene [5]; and the recently reported SCKL5 that
harbors mutations in CEP152 [6].
Cells derived from all Seckel patients are impaired in signaling
mediated by the DNA-damage responsive protein kinase ATR.
Thus, SS cells display reduced phosphorylation of downstream
ATR substrates, which include the Chk1 effector checkpoint
kinase, and impaired G2/M cell-cycle checkpoint arrest upon
treatment with UV light or replication blocking agents [7,8].
Except in SCKL1 patients where ATR itself is mutated, the
connections between the other SCKL loci and ATR activation are
not yet clear.
ATR is recruited to and activated by replication protein A
(RPA)-coated single-stranded DNA (ssDNA) [7], which arises by
uncoupling of DNA polymerases and helicases at stalled DNA
replication forks [9,10] or upon processing of DNA double-strand
breaks (DSBs) [7,9,11]. DSB processing occurs by DNA-end
resection, a 59-39 degradation of one of the DNA strands. This
process is a tightly regulated and serves as a molecular switch
between signaling mediated by the ATM and ATR kinases, and
also regulates the way DSBs are repaired [9]. Specifically,
resection only takes place effectively in S and G2 phases of the
cell cycle, and it is initiated by the combined actions of the
MRE11-RAD50-NBS1 (MRN) complex and CtIP [11]. The
licensing of DNA-end resection requires cell-cycle dependent
phosphorylation of CtIP [12,13], and in the absence of CtIP, DSB
processing is impaired and ATR activation is hampered [11].
PLoS Genetics | www.plosgenetics.org 1 October 2011 | Volume 7 | Issue 10 | e1002310As the above factors suggested that CtIP defects might yield SS,
we examined DNA samples from two unrelated microcephalic
families that both map to the SCKL2 locus: the original SCKL2
family [3] and a family diagnosed with a Seckel-like type of
congenital microcephaly termed Jawad syndrome [14] (see Figure
S1A and S1B). As described herein, this analysis revealed that the
affected individuals in these families indeed harbor homozygous
mutations in the CtIP gene. Strikingly, both mutations lead to
premature stop codons in the CtIP transcript and, therefore, to the
expression of predicted C-terminal truncation derivatives of CtIP.
We show that, while the Jawad two basepair deletion mutation
leads to a classical shift in reading frame, the SCKL2 mutation
creates an alternative splicing site leading to both the normal and
aberrant CtIP proteins coexisting in the cells of patients and
carriers. By characterizing SCKL2 cells and CtIP proficient cells
artificially expressing a C-terminally truncated CtIP protein, we
conclude that, despite being a recessively inherited syndrome, the
CtIP
SCKL2 mutation encodes a dominant negative protein that
impairs ATR activation.
Results
Like other SS cells, SCKL2 cells display defects in ATR
signaling in response to DSBs. However, in contrast to all other SS
cell lines tested, SCKL2 cells do not exhibit hypersensitivity to
replication fork stalling caused by hydroxyurea treatment[8]. As
the ATR pathway is activated by ssDNA exposed during
polymerase-helicase uncoupling under these circumstances, this
implies that ATR and the ATR signaling pathway are functional
in SCKL2 cells, and that the molecular defect of SCKL2 cells
responding to DSBs is likely upstream of ATR. Moreover, these
data suggest that SCKL2 cells might be specifically defective in
processing DSBs to ssDNA. Based on these and other criteria, we
sequenced the CtIP gene located within the SCKL2 locus
(18p11.31-q11.2; Figure 1A) [3] and found one mutation: a T to
G transition 53 bp within the 15
th intron (CtIP
s; Figure 1A). The
mutation co-segregated with the disease in the SCKL2 family and
was not present in 100 unrelated control individuals. All seven
members of the family were sequenced. No other mutations were
found despite in-depth sequencing of the promoter- and
untranslated regions (approximately 3500 bp), all coding exons
and adjacent intronic sequences (on average 750 bp).
Bioinformatics pointed to a 59 splice-attracting capability for the
altered sequence introduced by the CtIP
s mutation, suggesting the
presence of a competing alternative donor-site within the 15
th
intron (Figure S2). An alternative spliced transcript, resulting in an
extended exon 15 was thus expected. To assess this possibility, we
carried out RT-PCR amplifications targeting both this hypothe-
sized extended region (Figure 1C, 1D) and the wild-type transcript
sequence on total RNA extracted from EBV-transformed
lymphoblasts derived from SCKL2 patients, unaffected family
members and unrelated control individuals. No measurable
differences in expression were observed between the samples for
the wild-type isoform (not shown), but one weakly expressed CtIP
transcript, not previously identified, was specifically found in
samples from SCKL2 patients (homozygous) and at approximately
50% of this level in non-affected family members (heterozygous;
Figure 1B). We therefore denoted this transcript CtIP
Seckel.W e
observe uniform expression level of wild-type transcript between
cell lines, discarding a reduction in full length CtIP mRNA as a
cause for the observed phenotypes in SCKL2 patients and cell
lines. Due to the appearance of a premature stop codon, we
expected CtIP
Seckel transcript to be subjected to NMD and only
negligible levels to be expressed. Relative quantification of this
mutant transcript against wild type transcript showed in fact a
weak expression-ratio of approximately 1:600 in homozygous
SCKL2 cells (not shown). Sequencing the exon-intron junction of
CtIP
Seckel furthermore confirmed that the naturally occurring CtIP
exon 15 donor-site is indeed skipped in this transcript and that
RNA-splicing occurs between the introduced donor-site and the
exon 16 acceptor-site as predicted (Figure 1C). To test our
hypothesis that C-terminal truncation of CtIP can lead to
congenital microcephaly, we sequenced DNA samples from
several other patients suffering this type of condition. Some of
them came from a family diagnosed as suffering from Jawad
syndrome (Figure S1B) [14], previously mapped to chromosomal
region (18p11.22-q11.2) overlapping with the SCKL2 locus [14].
Jawad patients differ from Seckel patients as no growth-
impairment has been described for this syndrome. They do,
however, share a large number of other characteristics (see Table 1
for comparison of Seckel and Jawad symptoms). As it has been
shown that SS and primary microcephaly can be caused by the
same genes [15,16], we considered them good candidates for our
study. Indeed, in family members with Jawad syndrome, we found
a homozygous two base-pair deletion in exon 11 (CtIP
j; Figure 1A).
This 2 bp deletion causes a frame-shift in the CtIP reading frame
and the appearance of a premature stop codon that would yield a
truncated CtIP protein (Figure 1D and Figure S3). We also
analyzed DNA from two obligate carriers of the Jawad family and
found that both were heterozygous for the mutation. The
mutation was not present in any control individual.
It is notable that both the CtIP
s and CtIP
j mutations are
predicted to yield C-terminally truncated CtIP proteins
(CtIP
SCKL2 and CtIP
Jawad; Figure 1A and 1D, and Figure S3)
because C-terminal truncation of CtIP has been shown to cause
cells to display defective processing of DNA DSBs and exhibit
impaired ATR-dependent signaling [11]. Surprisingly, while
CtIP
j/j homozygotes presumably only express the truncated form
of the protein, CtIP
s/s homozygous cells express transcripts for
both the truncated and full-length CtIP proteins. We decided to
Author Summary
Cellular DNA is frequently damaged through the actions of
exogenous and endogenously arising DNA damaging
agents. To maintain genome integrity, cells have evolved
complex mechanisms to detect DNA damage, signal its
presence, and mediate its repair. The importance of such
mechanisms is evident because inherited defects in them
can cause embryonic lethality or severe genetically
inherited diseases. The clinical manifestations of such
diseases are complex and include growth delay, mental
retardation, skeletal abnormalities, and predisposition to
cancer. While most such syndromes are inherited reces-
sively, in some cases they are inherited dominantly. Here,
we show that mutations in CtIP/RBBP8 cause related
disorders: Seckel and Jawad syndromes. In addition to
revealing how mutated CtIP impairs responses to DNA
damage in Seckel cells, we establish that, despite the
recessive mode of inheritance for this syndrome, the
Seckel mutation has a dominant manifestation at the
cellular level. To our knowledge, this represents a new
form of molecular mechanism for recessive inheritance of a
human disease. Furthermore, the aberrantly spliced mRNA
is expressed at very low levels and yet significantly impairs
cellular functions and causes severe clinical symptoms.
This should provide new awareness that even very subtle
splice mutations may have pronounced pathogenic
potential.
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PLoS Genetics | www.plosgenetics.org 2 October 2011 | Volume 7 | Issue 10 | e1002310Figure 1. Schematics of the SCKL2 and Jawad loci and the CtIP gene, depicting the location of the identified mutations and
resulting transcript variants. (A) Genetic map of chromosome 18 with the SCKL2 and Jawad loci, defined by homozygous chromosomal
segments in affected consanguineous families. CtIP spans 93 kb of genomic sequence covering 19 exons (vertical bars), of which 18 are coding. Red
dots indicate positions of mutations and point to sequence electropherograms of homo- and heterozygous carriers and corresponding wild-type
sequence. (B) Quantitative RT-PCR, using primers targeting CtIP
Seckel, shows an aberrant transcript that is mutation-specific, expressed in a ratio of
approximately 1:0.5:0 in mutation homozygotes, heterozygotes and wildtype homozygotes. PCR on no-RT controls displayed similar threshold cycle
(CT) and melting curve profile as seen in +/+. Experiments were performed in triplicate and error bars represent s.d. (C) Sequencing of CtIP
Seckel and
wild-type CtIP transcripts, using same primers as in B, confirms that the 15
th exon/intron donor splice site is indeed partially skipped in SCKL2 patient
cDNA, and that splicing occurs between the competing donor-site and exon 16 acceptor-site. Corresponding amino acid sequences are shown for
both CtIP
Seckel and reference full-length CtIP. Red box indicate protein termination. (D) Schematic of wt CtIP and the expected CtIP
SCKL2 and CtIP
Jawad
proteins, with phosphorylation sites and functional regions.
doi:10.1371/journal.pgen.1002310.g001
Table 1. Comparison of clinical and morphometric findings in Seckel (SCKL2) and Jawad patients.
Seckel (SCKL2) Jawad
Appearance of symptoms Infancy Infancy
Birth weight (kg) Low (1 to 1.5) Data not available
Height (SD) Reduced (-3.5 to -5.5) Normal
Head circumference (SD) Reduced (-4.7 to -5.0) Reduced (-5.0 to -7.0)
Facial characteristics Narrow, not receding, forehead and prominent
noses. Small craniums.
Sharply receding foreheads, prominent noses. Small
craniums.
Global developmental delay Mild Moderate to severe
Skin abnormalities Cafe ´ au lait spots Cafe ´ au lait-like spots of white appearance
Digital malformation Phalangeal joint swellings, Clinodactyly Phalangeal joint swellings, Clinodactyly, Polydactyly,
Syndactyly, Total absence of nails
doi:10.1371/journal.pgen.1002310.t001
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molecular and cellular levels but, as no cellular or RNA samples
were available from the Jawad family, we focused our investiga-
tions on the SCKL2 family. According to in silico analyses of the
CtIP
Seckel transcript, its translation would end at a premature stop
codon shortly after the mutation site (Figure 1C and Figure S3).
These mRNA molecules are more likely subjected to NMD,
explaining the low abundance observed in SCKL2 cell lines.
However, the observed symptoms can not be explained by a
reduction in full-length CtIP transcript, as no changes in the
expression were observed in the different cell lines. Therefore, we
speculated that some of the truncated form of CtIP protein has to
be expressed in those cells and that the expression of this aberrant
form of CtIP is causing the disease. To test this hypothesis, we
analyzed CtIP in protein samples from lymphoblasts obtained
from a SCKL2 patient (CtIP
s/s), an asymptomatic family member
(CtIP
+/s) and an unrelated control individual (CtIP
+/+). As shown
in Figure 2A, no discernible changes in full-length CtIP protein
levels were observed between the different cell lines when using an
antibody raised against the CtIP C-terminus [17], in agreement
with no changes at the mRNA level and indicating that
accumulation of full-length CtIP is not compromised in SCKL2
patients. Notably, however, when using an antibody raised against
the CtIP N-terminus (Anti CtIP-Nt) [17], an additional shorter
protein species, undetectable in CtIP
+/+ lymphoblasts, was
observed in both CtIP
s/s and CtIP
+/s cell extracts (Figure 2A).
Unfortunately, this antibody seemed less specific than the one
raised against the C-terminus. Thus, to confirm that this band
truly represented a form of CtIP, we immunoprecipitated all forms
of the protein from etoposide treated cells by using an antibody
raised against the central part of the protein (Sigma) and blotting
with a different CtIP antibody (Novus Biological Ltd). Using this
approach we confirmed that in protein samples from CtIP
s/s and
CtIP
+/s lymphoblast a new, shorter species of CtIP of around 100
kDa appeared, whereas it was absent in the unrelated control
protein samples (Figure 2B). We therefore denoted this protein,
CtIP
SCKL2. Quantifying the abundance of this polypeptide
revealed that, despite the low abundance of the CtIP
Seckel transcript
in CtIP
s/s cells, the CtIP
SCKL2 protein is present in amounts
comparable to full-length CtIP (Figure 2C). An additional band
between full-length CtIP and CtIP
SCKL2 was also observed in all
three extracts with all the tested antibodies (Figure 2A and 2B,
double asterisk). We hypothesize that this represents an additional
form of CtIP, which is not related to the phenotypes we are
studying here. Alternative spliced CtIP mRNA has been found
previously and at the protein level at least one CtIP variant has
been isolated (Genbank Accession # NP_976037).
Full-length CtIP is hyper-phosphorylated upon DNA-damage in
a BRCA1-dependent manner by the apical checkpoint kinase
ATM [11,18,19] (Figure 2A, top panel; for phosphorylation sites,
see Figure 1D). Strikingly, although the truncated CtIP
SCKL2
protein retains the site required for its interaction with BRCA1
(Ser-327) [20] and contains all known sites for ATM-mediated
phosphorylation in response to DNA damage (Figure 1D) [18,19],
it was devoid of detectable DNA-damage induced modification as
assessed by changes in its electrophoretic mobility (Figure 2A),
suggesting that it represents a DNA-damage unresponsive form of
the protein. Accordingly, immunoprecipitation of a full length and
the truncated form of CtIP from etoposide treated lymphoblast
using the CtIP antibody from Sigma and blotting with antibodies
that recognize sites phosphorylated by ATM readily rendered a
strong phosphorylation signal of full-length CtIP but no signal for
the truncated protein (Figure 2D).
Because CtIP promotes DSB processing into RPA-coated
ssDNA required for ATR activation [11], we explored whether
CtIP
s/s cells were defective in this process. The RPA complex is
phosphorylated once it is bound to ssDNA, with Ser-4/Ser-8 (S4/
S8) phosphorylation of the RPA32 subunit being a readout of DSB
processing [11,12,21]. In line with our other findings, after treating
cells with the topoisomerase inhibitor etoposide, we observed that
CtIP
s/s cells exhibited reduced RPA32 S4/S8 phosphorylation as
compared with CtIP
+/+ cells, with the difference being most
evident at low etoposide doses (Figure 2A). In accordance with
these data and with SS being associated with defective ATR
activation [2,5], we also found that CtIP
s/s and CtIP
+/s cells
exhibited a mild defect in ATR signaling as measured by Chk1
phosphorylation, with this again being more evident at low
etoposide doses (Figure 2A; see Figure 2E for quantification).
Notably, cells from heterozygous CtIP
+/s also displayed small
impairments in RPA32 and Chk1 phosphorylation (Figure 2A and
2E), suggesting that heterozygous carriers of the CtIP
SCKL2 are
mildly defective in ATR signaling at the cellular level.
To explore things further, we analyzed a second readout for
DNA-end processing: RPA focus formation in cells treated with
etoposide. To avoid potential differences in numbers of damaged
cells, we quantified cells displaying cH2AX foci – which are well-
established markers for DSBs – and the proportion of these
cH2AX positive cells that also displayed RPA foci. Notably,
whereas the proportions of cells positive for cH2AX and RPA foci




exhibited a mild but significant reduction in etoposide-induced
RPA-focus formation (Figure 2E; see representative images on the
left and quantifications on the right). This decrease did not reflect
differences in cell cycle distributions (Figure S4) or rates of cell-
cycle progression because the amount of cH2AX positive cells was
similar for all three genotypes (Figure 2E). Similarly, when we
assessed cells for readouts of spontaneous DNA damage, which
most likely arises through replication forks encountering DNA
lesions, we found that the proportion of cH2AX positive cells that




+/s cells (Figure 2G).
Microcephaly, being a core manifestation of SS, is thought to
result from reduced proliferative potential in the developing
nervous system, most likely due to increased cell death of neuronal
stem cells or progenitor cells in the rapidly expanding fetal brain
[1]. As only lymphoblasts were available from SCKL2 patients, we
could not analyze their DNA-damage sensitivity by traditional




+/+ lymphoblast cells to the same density, treated them with
etoposide or DMSO as a control and then, at 24 hour intervals,
counted the number of total cells present together with the number
of viable cells in the cultures. As shown in Figure 3A and 3B, when
cells were mock-treated, they grew without a lag phase, with
similar growth rates being exhibited by all three genotypes. After
etoposide treatment, both the total number of cells and the
number of viable cells dropped in all cases. Notably, in accordance
with our other data, CtIP
+/+ cells recovered faster than CtIP
s/s
cells, whereas CtIP
+/s cells showed an intermediate response.
These findings correlated with higher levels of apoptosis, measured
by PARP cleavage, in CtIP
s/s cells as compared to CtIP
+/+
lymphoblasts, with CtIP
+/s cells once again displaying an
intermediate phenotype (Figure 3C). These results thus provided
indirect support for reduced proliferative potential being a factor
in the pathogenesis of the SCKL2 neuro-developmental disorder.
The mutated CtIP
SCKL2 protein is estimated to comprise 782
amino acid residues, whereas full-length CtIP comprises 897
residues. Interestingly, while CtIP
SCKL2 retains the CtIP dimer-
CtIP Causes Seckel Syndrome
PLoS Genetics | www.plosgenetics.org 4 October 2011 | Volume 7 | Issue 10 | e1002310Figure 2. SCKL2 cells express a shorter version of CtIP and are mildly defective in RPA-coated ssDNA formation and ATR activation.
(A) Protein samples from cells expressing the indicated CtIP variant after 1 h treatment with etoposide were separated by SDS-PAGE and detected
with the indicated antibodies. (B) CtIP was immunoprecipitated from protein extracts from the indicated cell lines treated with etoposide using an
anti-CtIP antibody (Sigma) and blotted using a different anti-CtIP (Novus Biological Ltd.). (C) Relative abundance of full-length CtIP and CtIP
SCKL2 in
different cell lines. (D) Immunoprecipitated CtIP from B were blotted with an antibody that recognized ATM and ATR phosphorylation sites (anti-
phospho S/TQ). (E) Relative abundance of Chk1 phosphorylated on Ser-345 with respect to total Chk1. Ratios were normalized to wild-type cells after
10 mM etoposide, taken as 100%. (F) Cells treated for 1 h with 10 mM etoposide were immunostained with RPA and cH2AX antibodies. The
percentages of total cells positive for cH2AX foci and proportions of cH2AX positive cells also positive for RPA foci are plotted. The averages and
standard deviations of three independent experiments are shown. (G) As in (F), but in cells not treated with etoposide.
doi:10.1371/journal.pgen.1002310.g002
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partners, it lacks residues 790-897 that promote MRN binding and
are required for DSB resection[11]. The region lost in CtIP
SCKL2
also lacks Thr-847, a key cyclin-dependent kinase (CDK) site that
controls CtIP activity in response to DNA damage [12,22], and
lacks two small regions conserved between CtIP and its yeast
counterparts Sae2 and Ctp1 (Figure 1D) [11,12,22,23]. These
issues suggested to us that CtIP
SCKL2 might not only be non-
functional in the DDR but might also act in a dominant-negative
manner in the context of the full-length CtIP protein that is also
expressed in SCKL2 cells (Figure 2A). To test this hypothesis, we
expressed green-fluorescent protein (GFP)-tagged C-terminally
truncated CtIP (CtIPDC) protein [11] in cells wild-type for CtIP,
and analyzed the impact of this on RPA focus formation after
etoposide treatment. Significantly, over-expression of GFP-
CtIPDC but not of GFP-CtIP full-length or GFP alone hampered
RPA-focus formation in primary human fibroblast and osteosar-
coma cells (Figure 4A and 4B).
The clinical manifestation of SCKL2 is inherited recessively;
that is, CtIP
+/s family members, while showing mild cellular
phenotypes that are intermediate between CtIP
s/s and CtIP
+/+
(Figure 2 and Figure 3), do not display overt clinical symptoms.
We therefore hypothesized that the ratio between the dominant
negative and full-length forms of CtIP might modulate the
strength of the defect in RPA-focus formation and ATR
signaling. To test this idea, we assessed RPA focus formation in
human osteosarcoma cells that had been transfected with both
GFP-CtIP and GFP-CtIPDC in varying ratios (Figure 4C; ratios
of transfected DNA are shown below the plot and the percentage
of CtIP that is full-length is stated below the western blot).
Strikingly, when more wild-type CtIP than CtIPDCw a s
transfected, no effect on RPA focus formation was observed.
However, once GFP-CtIPDC reached over 70% of total CtIP, a
moderate but significant reduction in RPA focus formation was
observed after etoposide treatment, with more substantial defects
in focus formation being observed at yet higher GFP-CtIPDC
levels (Figure 4C). Accordingly, Chk1 phosphorylation on Ser-
345 was also impaired once the ratio between GFP-CtIPDC and
CtIP full-length was above 70:30 (Figure 4D). These data
therefore supported a model in which the C-terminally truncated
CtIP protein serves as a dose-dependent dominant-negative
mutant.
Figure 3. Expression of the CtIP
SCKL2 causes DNA-damage hypersensitivity. (A,B) Cells expressing the indicated CtIP variant were grown to
,50,000 cells/ml, then split in two. Half of the culture was treated with 10 mM etopside and the rest was mock treated with DMSO. Samples were
taken every 24 h to determine cell number (A) and viability (B) by using a Cell Counting Kit-8 (see Methods for details), and normalized to the zero
time-point, taken as 1. The average and error of two independent experiments is plotted. (C) Protein samples from cells treated with 10 mM etoposide
collected at the indicated time-points were tested for the cleaved form of PARP1 as an apoptotic marker.
doi:10.1371/journal.pgen.1002310.g003
CtIP Causes Seckel Syndrome
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despite using increasing ratios of GFP-CtIPDC DNA, the amount
of CtIPDC protein rapidly saturated and was always considerably
higher than the full-length CtIP protein expressed from similar
amounts of plasmid. This therefore mimicked the situation in cells
from SCKL2 patients, in which low amounts of the CtIP
Seckel
transcript produced substantial amounts of CtIP
SCKL2 protein.
Notably, previous work has shown that CtIP is subject to a rapid
turnover mediated by the E3 Ubiquitin ligase SIAH1 [24], with
the interaction with SIAH1 being mapped to the CtIP C-terminus
[24]. To analyze the turnover of CtIPDC and full-length CtIP, we
transfected HEK293 cells with GFP-CtIPDC and FLAG-CtIP.
Although we were unable to co-immunoprecipitate SIAH1 either
with full-length or truncated CtIP (data not shown), we observed
Figure 4. CtIP
SCKL2 is an expression level-dependent dominant-negative protein. Primary human fibroblast (A; BJ) or osteosarcoma (B;
U2OS) cells were transfected with GFP alone or GFP-fusions of CtIP or CtIPDC. Two days later, cells were treated with 10 mM etoposide for 1 h, fixed
and immunostained for RPA and cH2AX. Percentages of cH2AX positive cells that were positive for RPA foci were determined, and averages and
standard deviations of three independent experiments are shown. (C) U2OS cells were transfected with a fixed amount of plasmid DNA comprising
different proportions of GFP-CtIP and GFP-CtIPDC. Cells were then treated as in (A), and (B), and the percentages of cH2AX positive cells that were
positive for RPA were calculated. Ratios between the transfected DNA of the truncated CtIP and full-length CtIP (GFP-CtIP) are shown above the
western blot for CtIP. Quantifications of protein levels and a calculation of percentages of dimers that represent homodimers of the full-length
protein, the truncated protein and heterodimers are shown below. (D) Protein samples from cells treated as in (C) were blotted for Chk1 as indicated.
Proportions of Ser-345 phosphorylated Chk1 versus total Chk1 were calculated and normalized to the sample transfected only with full-length CtIP,
taken as 100%.
doi:10.1371/journal.pgen.1002310.g004
CtIP Causes Seckel Syndrome
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CtIP was stabilized upon addition of the proteosome inhibitor
MG132 (Figure 5A). Along the same lines, inhibition of protein
synthesis by cycloheximide had a much more pronounced effect
on the levels of full-length CtIP than on CtIPDC (Figure 5B).
Collectively, these data suggested that the pathological form of
CtIP, CtIP
SCKL2, is not subject to normal proteosome dependent
turnover, thereby explaining how small amounts of an alternative
spliced transcript can produce enough protein to generate a
dominant negative effect.
CtIP activity relies on various protein-protein interactions,
including its homodimerization and interaction with MRN,
BRCA1, RB and PCNA. We explored the possibility that
truncated CtIP can sequester some or all of these partners. First,
we analyzed the ability of different forms of GFP-tagged CtIP to
be recruited to sites of DNA damage in the absence of
endogenous CtIP. To do so, we generated cell lines that stably
expressed siRNA-resistant GFP-tagged versions of full-length and
truncated CtIP, and then treated these cells with an siRNA
oligonucleotide to specifically target the endogenous CtIP. As
shown in Figure 5C, full-length CtIP and CtIPDC were recruited
with similar kinetics to sites of microirradiation (quantification in
Figure 5D; also see Videos S1 and S2). Similar results were
obtained when endogenous CtIP was present (that is, without
siRNA treatment; data not shown). Moreover, the residence times
at sites of DNA damage were almost identical for full-length CtIP
and CtIPDC (Figure 5E). These data supported a model in which
CtIPDC, previously shown to be non-functional, can localize to
sites of DNA damage but is then unable to effectively promote
ATR signaling and DNA repair. One possibility is that, as it still
retains an intact homo-dimerization domain, the truncated form
of CtIP can form an inactive hetero-dimer with full-length CtIP.
Consistent with this idea, immunoprecipitation of GFP-CtIPDC
from cells also expressing full-length FLAG-CtIP revealed that
the two proteins did indeed interact (Figure 5F, lane 1).
Strikingly, blocking the interaction of CtIPDC with full-length
CtIP by deleting the dimerization domain suppress its ability to
act as a dominant negative, supporting an scenario in which
CtIPDC sequester full-length CtIP (Figure 4B). Furthermore,
GFP-CtIPDC co-immunoprecipitated with the MRE11 subunit
Figure 5. CtIPDC acts as a dominant-negative subunit in CtIP complexes. (A) Cells transfected with full-length FLAG-CtIP and GFP-CtIPDC
were exposed to 10 mM MG132 for the indicated times. Protein extracts were resolved by SDS-PAGE and blotted with FLAG and GFP antibodies to
detect full-length and CtIPDC, respectively and tubulin as a loading control. (B) As in (A) but cells were treated with 150 mg/ml cycloheximide (CHX).
(C) U2OS cells stably transfected with GFP-CtIP or GFP-CtIPDC were siRNA-depleted for endogenous CtIP. Two days after, cells were micro-irradiated
(see Methods for details) to create DNA damage tracks. Cells were imaged live, taking pictures at maximum speed. (D) GFP accumulation from (C) was
measured by using ImageJ software and plotted using PRISM. N represents the number of cells analyzed. (E) Laser tracks from cells treated as in (C)
were subjected to FRAP (12 independent measurements; error bars s.d; see Methods for details). (F) Protein samples from cells transfected with GFP-
CtIPDC or GFP and with FLAG-CtIP or FLAG were immunoprecipitated by using a GFP-TRAP (Chromatek, see Methods for details) and then blotted
with the indicated antibodies.
doi:10.1371/journal.pgen.1002310.g005
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length CtIP (Figure 5F, lanes 1 and 2). Collectively, these data
supported the idea that the truncated form of CtIP acts in a
dominant-negative manner to partially impair DSB processing
and ATR activation.
Discussion
We have defined point mutations in CtIP associated with the
human congenital microcephaly syndromes, Seckel (SCKL2
family) and Jawad. Although the lack of biological samples from
the Jawad family prevented us from analyzing the predicted
appearance of the shorter species of CtIP mRNA and protein in
this case, we hypothesize that in each disease, the causative
mutation leads to a transcript with a premature stop codon,
yielding a C-terminally truncated form of CtIP that partially
hampers DSB resection and ATR activation. It is possible that in
the CtIP
j mutant, the shorter form of RNA will be subject to
nonsense-mediated decay (NMD) and no truncated protein will
be present. Although this may be the case, degradation of the
mutated CtIP
j transcript by NMD is unlikely to be complete, as it
has been shown that CtIP null mutants are embryonic lethal in
mice, at least in part due to their inability to overcome RB-
mediated G1 arrest [25]. Thus, we speculate that, in CtIP
j/j
patients, in whom the only form of the CtIP transcript is the
mutated one, some truncated protein will be present to allow the
G1/S transition. In this regard, we note that, even if the
transcript is largely degraded by NMD, the reduced turnover that
we have observed for C-terminally truncated CtIP (both the
CtIP
SCKL2 and GFP-CtIPDC) will allow enough protein to
accumulate to perform CtIP’s essential functions, while impairing
DNA resection.
Our results highlight similarities between CtIP-SCKL2 and
ATR-SCKL1. Notably, inactivation of either CtIP or ATR is
embryonic lethal in mouse, and in both SCKL1 and SCKL2, a
point mutation generates an alternative pre-mRNA splice site that
leads to the cellular and physiological phenotypes associated with
SS. However, in SCKL1, the aberrant mRNA form is not stable
and the shorter protein has never been detected in cells [2]. In this
case, the disease is caused by a reduction in the amount of full-
length ATR mRNA transcript that leads to reduced ATR protein
levels [2]. By contrast, in SCKL2 cells, no changes in the overall
levels of full-length mRNA or CtIP protein are observed (Figure 2A
and data not shown). Instead, the low abundance, shorter version
of the CtIP RNA is translated, producing a C-terminal CtIP
truncation mutant that seems to be more stable than the wild-type
protein, as much smaller amounts of mRNA are enough to
produce similar protein levels. In agreement with this model, we
have found that the levels of CtIPDC protein are less affected by
protein synthesis inhibition than full-length CtIP, and that levels of
the full-length but not the truncated form of CtIP is induced by
proteosome inhibition. Collectively, our data therefore indicate
that, in the case of SCKL2, it is the presence of this truncated CtIP
protein and not the reduction of full-length protein that causes the
cellular phenotypes. We hypothesize that the resulting inability of
SCKL2 cells to respond optimally to endogenously-arising DNA
damage lowers the apoptotic threshold in SCKL2 patient cells,
reduces their proliferative potential and thus causes the develop-
mental phenotypes observed in these patients.
Based on our analyses, we conclude that in SCKL2 patients,
the mutated, C-terminally truncated form of CtIP impairs DSB
processing and the formation of RPA-coated ssDNA. This
impaired ssDNA production thus partially hampers ATR
activation and results in hypersensitivity to DNA damage and
induction of apoptosis. Although most of our observations were
made when we used external sources of DNA-damaging drugs,
we also observed that SCKL2 cells exhibited reduced RPA DNA-
damage staining when grown in unperturbed conditions, possible
due to endogenously-arising DNA damage. It is noteworthy that
the predicted C-terminal truncated forms of CtIP in SCKL2 and
Jawad cells lack the normal CtIP C-terminus, which is a key
regulatory part of the protein. First, this region bears an MRN
interaction domain [11] that is crucial for DNA-end resection.
Although a second MRN interaction point has been found in the
very N-terminal part of the protein [26], the C-terminal region is
essential for CtIP-mediated activation of MRN-associated
nuclease activity. This could explain how, although GFP-CtIPDC
still interacts with the MRN complex, it renders the complex
unable to effectively perform DNA end resection [11]. Moreover,
the homology regions between CtIP and its budding yeast and
fission yeast counterparts Sae2 and Ctp1, respectively [23] are
also located at the C-terminal part of the CtIP protein that is
affected by the SCKL2 and Jawad mutations. In fact, the Thr-
847 CDK target site of CtIP, which is crucial for ssDNA
formation, is also missing in CtIP
SCKL2 and CtIP
Jawad [12,22].
Consistent with these issues, we have found that, unlike the wild-
type protein, CtIP
SCKL2 is not detectably phosphorylated in
response to DNA damage, despite it being able to hetero-
dimerize with the full-length CtIP protein and despite it retaining
sites for interaction with proteins such as BRCA1 and RB.
Consequently, we propose a model in which this DDR
unresponsive form of CtIP sequesters the full-length CtIP protein
and/or some of its interaction partners in unproductive
complexes, thereby blocking effective DSB processing. In accord
with such an idea, we have found that C-terminally truncated
CtIP is actively recruited to DNA damage sites with apparently
the same kinetics and residence time as full-length CtIP.
Moreover, CtIPDC species that are not able to interact with
full-length CtIP due to the deletion of the dimerization domain
lose the ability to act as a dominant negative, favouring this
model.
While we do not know why these complexes are inactive, an
attractive model is that CtIP acts as priming endonuclease, as has
been proposed for its budding yeast counterpart Sae2 [27]. In this
scenario, an initial endonucleolytic attack of the DNA molecule by
CtIP will create the substrate for the MRN complex. As many
nucleases work as dimers, it is possible than a CtIP/CtIP
SCKL2
dimers will be non functional, an idea supported by the fact that
Sae2 mutants lacking the C terminal part, conserved in CtIP, have
a partial impairment of its endonucleolytic activity [27].
Unfortunately, it has not yet been proved that CtIP can act as
an endonuclease. In fact, CtIP - as Sae2 - lacks of any putative
nuclease domain. Further biochemical work characterizing the
activity or activities of CtIP is needed to clarify this point.
Our findings also support a model in which the strength of the
phenotype caused by CtIP
SCKL2 depends on the ratio between the
levels of full-length and truncated forms of CtIP, presumably
because this ratio affects the levels of functional CtIP-containing
complexes. Consequently, it seems that a threshold of this ratio
must be surpassed in order to hamper ATR signaling sufficiently
to yield a measurable phenotype. Interestingly, this threshold
appears to be different for cellular and clinical symptoms because
heterozygous SCKL2 carriers do not manifest clinical symptoms
while they do present cellular phenotypes, albeit intermediate
between homozygous and wild-type cells. Consequently, a
dominant-negative form of CtIP causes SCKL2 Seckel syndrome
recessively. To our knowledge this is the first example of such type
of inheritance in man.
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Bioinformatics
Splice site predictions were evaluated by submitting the SCKL2
CtIP sequence from genomic position 18835580 to 18840493,





For mutation detection, PCR was done on genomic DNA using
intronic primers designed for amplification of all exons, including
both UTR regions and an average 200 bp exon/intron overlap
(Table S1). Cycle sequencing was performed directly on products.
For mutation analysis, RNA was isolated from EBV transformed B-
lymphoblastoid cell lines from SCKL2 family members and
unrelated healthy control individuals using ‘‘Nucleospin Total
RNA Isolation Kit II’’ according to manufacturer’s instructions.
RNA was eluted in 60 ml RNase-free H2O. RNA concentrations
were measured by optical density and purity of the RNA was
controlled by gel electrophoresis. cDNA was made using
‘‘iScriptTM Select cDNA Synthesis Kit’’ with mix of random
hexamer and poly-dT primers using 1 mg of total RNA as synthesis
template. Remaining procedures were according to manufacturer’s
protocols. For mutation-specific PCR, Roche Expand High Fidelity
PCR System enzyme mix was used. The PCR solution was mixed
up to a total volume of 20 ml consisting of: 2 ml cDNA elution
(diluted 1:10), 2 ml 10xPCR buffer (Roche), 0.4 ml dNTP (0.2 mM
final concentration) 0.6 ml of each primer (0.3 mM final concentra-
tion) (forward primer: TGGTTAGTGAAACCGTTCTCTT and
reverse primer: TGCAACTGAGAAGCCATAATTAAA), 0.1 ml
Taq polymerase (5U/ml) and variousproportions of MgCl2, DMSO
and dH2O. Reactions consisted of 2 min at 94uC followed by 38
cycles of 30 sec at 94uC, 30 sec at 60uC and 1.5 minutes at 72uC,
ending with 8 min at 72uC. The PCR products were purified by gel
electrophoresis, extracted and directly sequenced.
Transcript quantification
Transcript expression was examined by qRT-PCR using the
LightCycler 480 Real-Time PCR System (Roche diagnostics) and
the DNA-binding dye SYBR Green (Invitrogen Corporation,
Carlsbad, California, USA). For CtIP
wt and CtIP
Seckel comparison
within the same cell lines, 2 primer-pairs were designed to
specifically target each of the transcripts (Primer sequences are
available upon request) and were run in parallel with 2 in-house
validated normalizers. Expression levels between cell lines were
examined using one target primer-pair for each transcript
normalized to above-mentioned normalizers. cDNA from two
independent iScript (Bio-Rad Laboratories, Inc.) reactions were
analyzed for all samples which were run in triplets. SYBR Green
amplification mixtures (10 ml reactions) contained SYBR Green
master mix, 0,5 mM of each forward and reverse primer, and 2 ml
of template cDNA. The PCR cycling conditions were as follows:
109 at 95uC, followed by 40 cycles of 100 at 95uC, 200 at 60uC and
300 at 72uC. After PCR amplification, a melting curve was
generated for every PCR product to check the specificity of the
PCR reaction (absence of primer dimers or other nonspecific
amplification products). Each assay included a no-template
control. The threshold cycle (Ct) values of LightCycler 480
Software, Version 1.5 (Roche diagnostics) were exported to Excel
(Microsoft Corp., Seattle, Washington, USA) for relative quanti-
fication analysis using a modified delta-delta Ct method with
efficiency correction.
Cell culture, siRNA, and plasmid transfections
EBV transformed lymphoblasts were grown in RPMI buffer
containing 15% fetal bovine serum (BioSera), 100 units/ml of
penicillin, and 100 mg/ml of streptomycin (Sigma-Aldrich). BJ and
U2OS cells were grown in DMEM (Sigma-Aldrich) supplemented
with 10% fetal bovine serum, 100 units/ml of penicillin, and
100 mg/ml of streptomycin. Transient transfection of GFP-CtIP,
GFP-CtIPDC and GFP was with a microporator (MicroPorator)
following the manufacturer’s protocols. Experiments were per-
formed 48 h after transfection.
Immunoblotting
Extracts were prepared in Laemmli buffer (4% SDS, 20%
glycerol, 120 mM Tris-HCl pH 6.8), proteins were resolved by
SDS-PAGE and transferred to nitrocellulose followed by immu-
noblotting. R. Baer (Columbia University) provided the mouse
monoclonal antibodies raised against the CtIP C-terminus or N-
terminus. Other antibodies were from Novus Biological (CtIP),
Sigma (CtIP, Tubulin), Abcam (RPA32), Bethyl Laboratories
(RPA32-pS4/S8), Cell Signaling Technology (PARP, phospho-
S345 Chk1) and Santa Cruz (Chk1). Western quantification was
performed using additional blots, equally loaded to the ones shown
in the figures and scanned with a LI-COR Odyssey infrared
imaging system.
Protein stability analyses
Cells were transfected with FLAG-CtIP and GFP-CtIPDC. Two
days after transfection, cells were treated with 10 mM MG132
(Sigma) or 150 mg/ml cycloheximide (Sigma). At the indicated
times, cells were washed with ice cold PBS and collected in
Laemmli buffer. Proteins were resolved by SDS-PAGE and
blotted with an anti-Flag (Sigma) or anti-GFP (Roche) antibody as
indicated.
Co-immunoprecipitation
Cells transfected with GFP-CtIPDC or GFP and either FLAG-
CtIP or FLAG, were grown for two days and then collected in
RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA and 0.1% SDS). GFP
immunoprecipitation was performed by using a GFP-Trap
(Chromotek), following the manufacturer’s instructions. After
protein electrophoresis and transfer to nitrocellulose filters,
membranes were blotted with anti-GFP (Roche), anti-FLAG
(Sigma) or anti-Mre11 (Novus Biological).
CtIP immunoprecipitation from lymphoblasts
Cells were colleted by centrifugation, washed twice with ice cold
PBS and resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4,
1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA and 0.1% SDS). Immunoprecipitation was performed by
using a CtIP antibody from Novus. After protein electrophoresis
and transfer to nitrocellulose filters, membranes were blotted with
anti-CtIP from Sigma or anti-phospho S/TQ (Novus Biological).
Immunofluorescence microscopy
For RPA focus detection, lymphoblasts were treated with
10 mM of etoposide or DMSO. One hour afterwards, cells were
washed twice with PBS and deposited on coverslips using a
CytoSpin funnel on a CytoCentrifuge. Following pre-extraction
for 5 min on ice (25 mM Hepes pH 7.4, 50 mM NaCl, 1 mM
EDTA, 3 mM MgCl2, 300 mM sucrose and 0.5% Triton X-100),
cells were fixed with 4% paraformaldehyde (w/v) in PBS for
15 min. Cover-slips were washed three times with PBS and then
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Technology) and RPA32 (Lab Vision). For detection, Alexa Fluor-
594 (red) and -488 (green) conjugated secondary antibodies were
used (Molecular Probes, Paisley, UK). Samples were visualized
with an Olympus upright confocal microscope by sequential
scanning of the emission channels. U2OS and BJ cells transfected
with GFP fusions were grown on cover-slips for two days after
transfection, treated with etoposide as described and fixed and co-
immunostained as above, with the exception that Alexa Fluor-594
(red) and -647 (far red) conjugated secondary antibodies were
used.
Laser micro-irradiation and FRAP analyses
Localized DNA damage was generated by exposing cells to a
UV-A laser [28,29]. Cells plated on glass-bottomed dishes
(Willco Wells) and were pre-sensitized with 10 mM 5-bromo-20
deoxyuridine (BrdU, Sigma-Aldrich) in phenol red-free medi-
um (Invitrogen) for 24 h at 37uC. Micro-irradiation was with a
FluoView 1000 confocal microscope (Olympus) equipped with
a3 7 uC heating stage (Ibidi) and a 405 nm laser diode (6 mW)
focused through a 60X UPlanSApo/1.35 oil objective to yield a
spot size of 0.5 to 1 mm. Time of cell exposure to the laser
beam was ,250 ms (fast-scanning mode). Laser settings
(0.40 mW output, 50 scans, SIM scanner) were chosen to
generate a detectable DDR restricted to the laser path in a pre-
sensitization-dependent manner without detectable cytotoxic
effects. FRAP analyses were performed on the microscope used
for laser micro-irradiation when the accumulation of the GFP-
tagged protein on the laser track reached its maximal steady-
state level. After a series of three pre-bleach images, a
rectangular region placed over the laser-damaged line was
subjected to a bleach pulse (five scans with 488 nm argon laser
focused through a 360 UPlanSApo/1.35 oil objective, main
scanner, 100% AOTF acousto-optical tunable filter, slow
scanning mode), followed by image acquisition at fastest speed.
Average fluorescent intensities in the bleached region were
normalized against intensities in an undamaged nucleus in the
same field after background subtraction to correct for overall
bleaching of the GFP signal due to repetitive imaging. For
mathematical modelling of GFP-tagged protein mobility,
(It - I0)/Ipre values were plotted as a function of time, where
I0 is the fluorescence intensity immediately after bleaching and
Ipre is the average of the three pre-bleach measurements.
Estimation of mobile protein fraction (A) and residence time (t)
were performed using Prism 4 software assuming the existence
of one protein population using the following equation: y(t)
=A(1 - exp(-t/t)).
Cell-cycle distributions (flow cytometry)
To determine cell-cycle distributions, cells were fixed with 70%
ethanol, incubated for 30 min with RNase A (250 mg/ml) and
propidium iodide (10 mg/ml) at 37uC. For each experiment 10
4
cells were analyzed for fluorescence and recorded by a FACSAria
flow cytometer (Becton Dickinson, Mountain View, CA); cell
debris was excluded on the basis of forward and side light-
scattering properties. Cell cycle distribution was determined from
DNA fluorescence histograms using the CellFit software (Becton
Dickinson).
Cell survival assays
Cells were grown to ,50,000 cells/ml, and then split in two.
Half of the culture was treated with 10 mM of etoposide, and the
rest was mock treated with DMSO. A sample was taken every
24 h for 10 days to determine cell number/viability. Cell numbers
were determined by direct counting with a Beckman Coulter Cell
and particle counter. Viable cell were measured with a Cell
Counting Kit-8 (Dojindo Lab., Kumamoto, Japan) following the
manufacturer’s instructions.
Supporting Information
Figure S1 Pedigrees of consanguineous families investigated. A
Jawad Family. B SCKL2 Family.
(PDF)
Figure S2 Schematics showing splice-site prediction of the
altered 15th exon/intron transition. Upper panels indicate coding
potential; middle panels represent donor-site predictions; lower
panels represent acceptor-site predictions. Coloured lines: variable
90% threshold. Encircled numbers 1/2 indicate exon 15 wild-type
(wt) acceptor-/donor-site; 3 indicates donor-site introduced by the
CtIPs mutation; and 4/5 indicate exon 16 wt splice-sites.
(PDF)
Figure S3 Sequence alignment of the C-termini of full-length
CtIP, CtIP
SCKL2 and CtIP
Jawad. Alternative splicing of the
CtIP
Seckle transcript leads to a 20 amino acid sequence change
(aa 763 to 782) and a C-terminal truncation. The 2 base-pair
deletion in CtIP
Jawad changes the reading frame and leads to a 5
amino acid sequence change (aa 603-607) and a larger C-terminal
deletion than in CtIP
SCKL2. Red letters mark where sequences
differ.
(PDF)
Figure S4 Cell cycle distributions for lymphoblastoid popu-
lations. Cells were obtained from the SCKL2 family (s/s and +/
s, representing homozygous and heterozygous cells for the
CtIP
s mutation, respectively) and a healthy unrelated control
individual (bottom). The percentages of cells in each phase of
the cell cycle are represented in graphs. See methods for further
details.
(PDF)
Table S1 List of primers used for mutational analysis. Pair of
primers (F:Forward and R: Reverse) that anneal at introns were
used to amplify genomic DNA. PCR products were directly
sequenced. See Methods for details.
(DOC)
Video S1 Accumulation of wild type CtIP at sites of laser
microirradiation. Cells expressing GFP-tagged full length CtIP
were laser microirradiated and filmed at maximum acquisition
speed.
(MOV)
Video S2 Accumulation of truncated CtIP at sites of laser
microirradiation. Cells expressing GFP-tagged C-terminal trun-
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